{"id":1001079,"date":"2026-09-08T07:37:14","date_gmt":"2026-09-08T11:37:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-september-investor-conferences\/"},"modified":"2026-09-08T07:37:14","modified_gmt":"2026-09-08T11:37:14","slug":"cervomed-to-participate-in-september-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-september-investor-conferences\/","title":{"rendered":"CervoMed to Participate in September Investor Conferences"},"content":{"rendered":"
\n

BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) — CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (“CervoMed” or the “Company”), today announced that Company management will participate in the following investor conferences during the month of September:<\/p>\n

\n Cantor Global Healthcare Conference <\/strong>
\n
Format: Fireside Chat & 1×1 Investor Meetings
Date:\u00a0Friday, September 11, 2026
Time: 10:55 \u2013\u00a011:25 AM ET<\/p>\n

Webcast Link:
https:\/\/sqps.onstreamsecure.com\/origin\/enliven\/players\/EnlivenPlayer.html?customerId=22&eventId=43787678&checkCompany=1&checkEmail=1&checkName=1<\/a><\/p>\n

\n H.C. Wainwright Global Investment Conference<\/strong>
\n
Format: Presentation & 1×1 Investor Meetings
Date: Tuesday, September 15, 2026
Time: 4:00 \u2013 4:30 PM ET<\/p>\n

Webcast Link:\u00a0
https:\/\/journey.ct.events\/view\/9a19abdb-8a2c-4742-bae3-a2dbdb363f7f<\/a><\/p>\n

\n About CervoMed<\/strong>\n <\/p>\n

CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed\u2019s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in patients with DLB, enriched for those without AD co-pathology, and the Company announced alignment with the FDA on a potential registration path for neflamapimod in DLB in November 2025. Initiation of a Phase 3 trial in DLB is subject to the establishment of a partnership and\/or additional financing. CervoMed also recently completed enrollment in its ongoing Phase 2a clinical trial evaluating neflamapimod in nfvPPA, a subtype of frontotemporal disorders, from which interim biomarker data is anticipated in the early fourth quarter of 2026, and expects the first patient to be dosed with neflamapimod in the EXPERTS-ALS Phase 2a clinical trial in the fourth quarter of 2026.<\/p>\n

\n Contacts:<\/strong>\n <\/p>\n

\n Media:<\/strong>
\n
Lisa Guiterman
Biongage Communications
lisa.guiterman@gmail.com<\/a>
202-330-3431<\/p>\n

\n Investor Relations:<\/strong>
\n
Argot Partners
cervomed@argotpartners.com<\/a>
212-600-1902\u00a0<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) — CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (“CervoMed” or the “Company”), today announced that Company management will participate in the following investor conferences during the month of September: Cantor Global Healthcare Conference Format: Fireside Chat & 1×1 Investor MeetingsDate:\u00a0Friday, September 11, 2026Time: 10:55 \u2013\u00a011:25 AM ET Webcast Link: https:\/\/sqps.onstreamsecure.com\/origin\/enliven\/players\/EnlivenPlayer.html?customerId=22&eventId=43787678&checkCompany=1&checkEmail=1&checkName=1 H.C. Wainwright Global Investment Conference Format: Presentation & 1×1 Investor MeetingsDate: Tuesday, September 15, 2026Time: 4:00 \u2013 4:30 PM ET Webcast Link:\u00a0https:\/\/journey.ct.events\/view\/9a19abdb-8a2c-4742-bae3-a2dbdb363f7f About CervoMed CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting … <\/p>\n

Continue reading “CervoMed to Participate in September Investor Conferences”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1001079","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCervoMed to Participate in September Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-september-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CervoMed to Participate in September Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) — CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (“CervoMed” or the “Company”), today announced that Company management will participate in the following investor conferences during the month of September: Cantor Global Healthcare Conference Format: Fireside Chat & 1×1 Investor MeetingsDate:\u00a0Friday, September 11, 2026Time: 10:55 \u2013\u00a011:25 AM ET Webcast Link: https:\/\/sqps.onstreamsecure.com\/origin\/enliven\/players\/EnlivenPlayer.html?customerId=22&eventId=43787678&checkCompany=1&checkEmail=1&checkName=1 H.C. Wainwright Global Investment Conference Format: Presentation & 1×1 Investor MeetingsDate: Tuesday, September 15, 2026Time: 4:00 \u2013 4:30 PM ET Webcast Link:\u00a0https:\/\/journey.ct.events\/view\/9a19abdb-8a2c-4742-bae3-a2dbdb363f7f About CervoMed CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting … Continue reading "CervoMed to Participate in September Investor Conferences"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-september-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-08T11:37:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTI3NCM3ODE3NzQ2IzIxODQ1ODU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-september-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-september-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CervoMed to Participate in September Investor Conferences\",\"datePublished\":\"2026-09-08T11:37:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-september-investor-conferences\\\/\"},\"wordCount\":293,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-september-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMTI3NCM3ODE3NzQ2IzIxODQ1ODU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-september-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-september-investor-conferences\\\/\",\"name\":\"CervoMed to Participate in September Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-september-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-september-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMTI3NCM3ODE3NzQ2IzIxODQ1ODU=\",\"datePublished\":\"2026-09-08T11:37:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-september-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-september-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-september-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMTI3NCM3ODE3NzQ2IzIxODQ1ODU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMTI3NCM3ODE3NzQ2IzIxODQ1ODU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-to-participate-in-september-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CervoMed to Participate in September Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CervoMed to Participate in September Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-september-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"CervoMed to Participate in September Investor Conferences - Market Newsdesk","og_description":"BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) — CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (“CervoMed” or the “Company”), today announced that Company management will participate in the following investor conferences during the month of September: Cantor Global Healthcare Conference Format: Fireside Chat & 1×1 Investor MeetingsDate:\u00a0Friday, September 11, 2026Time: 10:55 \u2013\u00a011:25 AM ET Webcast Link: https:\/\/sqps.onstreamsecure.com\/origin\/enliven\/players\/EnlivenPlayer.html?customerId=22&eventId=43787678&checkCompany=1&checkEmail=1&checkName=1 H.C. Wainwright Global Investment Conference Format: Presentation & 1×1 Investor MeetingsDate: Tuesday, September 15, 2026Time: 4:00 \u2013 4:30 PM ET Webcast Link:\u00a0https:\/\/journey.ct.events\/view\/9a19abdb-8a2c-4742-bae3-a2dbdb363f7f About CervoMed CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting … Continue reading \"CervoMed to Participate in September Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-september-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-08T11:37:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTI3NCM3ODE3NzQ2IzIxODQ1ODU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-september-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-september-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CervoMed to Participate in September Investor Conferences","datePublished":"2026-09-08T11:37:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-september-investor-conferences\/"},"wordCount":293,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-september-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTI3NCM3ODE3NzQ2IzIxODQ1ODU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-september-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-september-investor-conferences\/","name":"CervoMed to Participate in September Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-september-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-september-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTI3NCM3ODE3NzQ2IzIxODQ1ODU=","datePublished":"2026-09-08T11:37:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-september-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-september-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-september-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTI3NCM3ODE3NzQ2IzIxODQ1ODU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTI3NCM3ODE3NzQ2IzIxODQ1ODU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-to-participate-in-september-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CervoMed to Participate in September Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1001079","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1001079"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1001079\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1001079"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1001079"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1001079"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}